By Suzanne Shelley, Contributing Editor

The longstanding adherence problem is yielding to new technology

The widening scope of RWE data available from patients is changing both clinical and post-approval practices for drug development

An ‘overwhelming’ information load is affecting oncology’s ability to develop successful treatment pathways

The ‘age in place’ trend creates challenges for market access to seniors

Existing incentives continue to draw in new drug developers; payers begin to look at competitive markets to drive down drug costs

The scale of the cardiovascular market pushes payers to demand quality outcomes data

A raft of new therapies is generating renewed optimism for cancer care, but even as lower-cost biosimilars enter the market, cost is a crippling factor